Cargando…
The impact of using primaquine without prior G6PD testing: a case series describing the obstacles to the medical management of haemolysis
Radical cure of Plasmodium vivax malaria in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals employs weekly primaquine dosing. This is the only recommended regimen for this patient sub-group. If national malaria programs mandate daily primaquine dosing (the recommended regimen for G6PD...
Autores principales: | Chu, Cindy S., Bancone, Germana, Soe, Nay Lin, Carrara, Verena I., Gornsawun, Gornpan, Nosten, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480970/ https://www.ncbi.nlm.nih.gov/pubmed/31069260 http://dx.doi.org/10.12688/wellcomeopenres.15100.2 |
Ejemplares similares
-
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
por: Chu, Cindy S., et al.
Publicado: (2018) -
Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects
por: Bancone, Germana, et al.
Publicado: (2016) -
Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood
por: Bancone, Germana, et al.
Publicado: (2018) -
G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
por: Bancone, Germana, et al.
Publicado: (2021) -
The reality of using primaquine
por: Burgoine, Kathy L, et al.
Publicado: (2010)